Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH (Reuters) - Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.